Cibinetide (ARA-290), 20 mg, lyophilized laboratory reference material vial
RESEARCH PEPTIDE

ARA-290 PEPTIDE | MOLECULAR & ANALYTICAL RESEARCH

Cibinetide (ARA-290) — EPO-Derived Repair-Receptor Research Peptide
$89.00
EPO-helix-B-derived peptide supplied as a lyophilized laboratory reference material for proposed innate-repair-receptor signaling research. Research use only. Not for human or veterinary use.
✓ Scientific Identity Established
⏳ Laboratory Testing In Progress
⏳ Batch Documentation Pending
✓ Research Use Only
✓ U.S. Fulfillment
In Laboratory Testing
Lot Verification Variant-specific documentation
Traceable Lots VBL lot identification
Primary Literature Peer-reviewed sources
Research Use Only Laboratory research materials

Scientific Specifications

Reference characteristics for laboratory research materials.

CAS Number
1208243-50-8
Molecular Formula
C51H84N16O21
Molecular Weight
1257.31
Research Classification
Research Use Only (RUO). Not for human or veterinary use.

SCIENTIFIC OVERVIEW

Scientific background and research classification for this laboratory reference material.

Cibinetide (ARA-290; pHBSP) is a synthetic 11-residue peptide derived from the solvent-exposed face of erythropoietin helix B, with N-terminal pyroglutamate and a free-acid C-terminus. It is distinct from erythropoietin and supplied as a laboratory reference material. Research use only.

Primary Research Category
Immune Regulation
Material Type
Lyophilized Peptide
Intended Use
Laboratory Research
Research Categories
Innate Immunity Inflammation Neuroprotection

Mechanism of Action

Molecular interaction profile describing how this research material engages receptor systems and influences downstream biological signaling pathways.

Published experimental models report signaling associated with a proposed EPOR/CD131 heteromeric receptor complex. Receptor composition and selectivity remain under study, and downstream findings are confined to the stated models.

Primary Organ Systems
  • Immune System
  • Central Nervous System
  • Metabolic System

Research Documentation

Laboratory documentation is presented when available for the selected product specification and current lot.

In Laboratory Testing
Laboratory Documentation In Progress

Laboratory documentation for the current lot is being completed.

Scientific References
Peer-Reviewed Literature

Explore published literature, clinical investigations, and foundational scientific research.

View References →
Laboratory Resources
Technical Guidance

Storage guidance, handling recommendations, analytical methods, and laboratory best practices.

Related Research
Companion Materials

Discover complementary research materials frequently studied alongside this compound.

Research Center

Scientific literature, laboratory resources, and related materials curated to support research involving this research material.

Scientific References
Peer-Reviewed Literature

Explore curated publications from peer-reviewed journals including clinical investigations, mechanistic studies, and foundational scientific literature.

Browse References →
Scientific Dossier
Deeper Technical Treatment

Comprehensive scientific documentation including literature review, mechanism, pharmacology, and study data for this research material.

Laboratory Resources
Technical Guidance

Storage guidance, handling information, analytical standards, research policies, and laboratory support documentation.

Research Library

Curated peer-reviewed literature selected to provide scientific context for this research material.

Mechanistic Study•PNAS• 2008

Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin

Foundational report identifying the 11-residue helix-B-surface peptide and nonerythropoietic tissue-protective activity in experimental models.
Velora Research Insight
Included as scientific context at the stated evidence level; no finished-lot or therapeutic inference.
PubMed →DOI →
Clinical Trial•Molecular Medicine• 2012

Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study

Randomized pilot study of ARA-290 in a defined sarcoidosis-associated small-fiber-neuropathy population.
Velora Research Insight
Included as scientific context at the stated evidence level; no finished-lot or therapeutic inference.
PubMed →DOI →
Clinical Trial•Molecular Medicine• 2013

ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density

Human clinical study evaluating symptom and corneal nerve-fiber-density endpoints.
Velora Research Insight
Included as scientific context at the stated evidence level; no finished-lot or therapeutic inference.
PubMed →DOI →
Clinical Trial•Molecular Medicine• 2014

ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes

Phase-2 study of ARA-290 in type-2 diabetes with metabolic and neuropathic endpoints; continued evaluation was recommended.
Velora Research Insight
Included as scientific context at the stated evidence level; no finished-lot or therapeutic inference.
PubMed →DOI →